Open-label, active-control, phase 2/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma.

被引：0
|
作者：
Cobb, Patrick Wayne
Zhou, Heng
Nahar, Akash
Marinello, Patricia
机构：
[1] St Vincent Healthcare Canc Ctr Montana, Billings, MT USA
[2] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7592
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
    Terui, Yasuhito
    Rai, Shinya
    Izutsu, Koji
    Yamaguchi, Motoko
    Takizawa, Jun
    Kuroda, Junya
    Ishikawa, Takayuki
    Kato, Koji
    Suehiro, Youko
    Fukuhara, Noriko
    Ohmine, Ken
    Goto, Hideki
    Yamamoto, Kazuhito
    Kanemura, Nobuhiro
    Ueda, Yasunori
    Ishizawa, Kenichi
    Kumagai, Kyoya
    Kawasaki, Atsuko
    Saito, Tomohisa
    Hashizume, Misato
    Shibayama, Hirohiko
    CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854
  • [2] Phase 2, open-label study of CUDC-907 with and without rituximab in patients with relapsed/refractory MYC-altered diffuse large B-cell lymphoma.
    Landsburg, Daniel Jeffrey
    Kelly, Kevin
    Viner, Jaye
    Wang, Jing
    Gong, Lucy
    Clancy, Myles Steven
    Ma, Anna W.
    Oki, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE®) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Viardot, Andreas
    Goebeler, Mariele
    Pfreundschuh, Michael
    Adrian, Nicole
    Libicher, Martin
    Degenhard, Evelyn
    Stieglmaier, Julia
    Zhang, Alicia
    Nagorsen, Dirk
    Bargou, Ralf C.
    BLOOD, 2013, 122 (21)
  • [4] Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study
    Santoro, Armando
    Johnson, Nathalie A.
    Savage, Kerry J.
    Avigdor, Abraham
    Bazargan, Ali
    Borchmann, Peter
    Gasiorowski, Robin
    Gregory, Gareth P.
    Herishanu, Yair
    Madan, Sumit
    Minuk, Leonard
    Musuraca, Gerardo
    West, Rachel Marceau
    Pillai, Pallavi
    Marinello, Patricia
    Zinzani, Pier Luigi
    BLOOD, 2023, 142
  • [5] An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma
    Younes, Anas
    Salles, Gilles
    Bociek, R. Gregory
    Martinelli, Giovanni
    Caballero, Dolores
    Gonzalez Barca, Eva
    Mukherjee, Nabanita
    Williams, Lisa
    Herbst, Fabian
    Tavorath, Ranjana
    Kim, Won Seog
    BLOOD, 2014, 124 (21)
  • [6] A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
    Larsen, Thomas S.
    Manzke, Oliver
    Leibovitz, Daniel
    Arbushites, Michael
    BLOOD, 2022, 140 : 12077 - 12078
  • [7] A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Zhu, Jun
    Song, Yuqin
    Guo, Ye
    Zhou, Keshu
    Li, Wenyu
    Yang, Yu
    Cai, Qingqing
    Wang, Zhao
    Yang, Haiyan
    BLOOD, 2023, 142
  • [8] Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients
    Song, Yuqin
    Zhang, Qingyuan
    Cai, Qingqing
    Song, Yongping
    Zhang, Liling
    He, Pengcheng
    Wang, Li
    Hirata, Jamie
    Musick, Lisa
    Deng, Rong
    Liu, Wenxin
    Wang, Xin
    Zhu, Jun
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (07)
  • [9] A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Kambhampati, Swetha
    Kallam, Avyakta
    Borogovac, Azra
    Chen, Lu
    Puverel, Sandrine
    Johnson, Jennifer
    Melgar, Ivana
    Baird, John H.
    Danilov, Alexey
    Godfrey, James
    Khan, Niloufer
    Mei, Matthew
    Phillips, Tycel J. J.
    Siddiqi, Tanya
    Shouse, Geoffrey
    Zain, Jasmine
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Song, Joo Y.
    Herrera, Alex F.
    Budde, Elizabeth
    BLOOD, 2024, 144 : 17421 - 17422
  • [10] An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma
    Morschhauser, Franck
    Salles, Gilles
    Le Gouill, Steven
    Tilly, Herve
    Thieblemont, Catherine
    Bouabdallah, Krimo
    Fabiani, Bettina
    Menard, Cedric
    Tarte, Karin
    Cartron, Guillaume
    Houot, Roch
    BLOOD, 2018, 132 (14) : 1486 - 1494
12345